ProQR Therapeutics NV
PRQR1.500USD
+0.040+2.74%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
161.57M시가총액
손실P/E TTM
자세한 내용은 ProQR Therapeutics NV 회사
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV 정보
종목 코드 PRQR
회사 이름ProQR Therapeutics NV
상장일Sep 18, 2014
CEOde Boer (Daniel Anton)
직원 수166
유형Ordinary Share
회계 연도 종료Sep 18
주소Zernikedreef 9
도시LEIDEN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Netherlands
우편 번호2333 CK
전화31881667000
웹사이트https://www.proqr.com/
종목 코드 PRQR
상장일Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
기타
54.92%
주주
주주
비율
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
기타
54.92%
주주 유형
주주
비율
Hedge Fund
18.45%
Corporation
16.07%
Family Office
14.60%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
5.66%
Research Firm
3.13%
Individual Investor
2.03%
기타
29.10%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
118
40.27M
38.22%
-4.52M
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.25M
5.94%
-348.47K
-5.28%
Sep 30, 2025
Privium Fund Management BV
5.00M
4.74%
+725.00
+0.01%
Sep 30, 2025
Affinity Asset Advisors LLC
3.60M
3.42%
+100.49K
+2.87%
Sep 30, 2025
abrdn Inc.
2.30M
2.18%
+448.48K
+24.24%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.89M
2.75%
-171.79K
-5.61%
Sep 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
--
--
Sep 30, 2025
Kynam Capital Management LP
1.65M
1.57%
--
--
Sep 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
비율0.01%
Avantis International Small Cap Value ETF
비율0%
Invesco NASDAQ Future Gen 200 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
